XML 105 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
Commitments and Contingencies - Contingencies - Additional Information (Detail)
€ in Millions
 1 Months Ended 9 Months Ended 12 Months Ended 48 Months Ended
Dec. 31, 2023
USD ($)
Nov. 09, 2022
USD ($)
Jun. 02, 2022
USD ($)
Jul. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2013
USD ($)
Apr. 30, 2013
USD ($)
Aug. 31, 2012
USD ($)
Dec. 31, 2010
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2014
USD ($)
Aug. 21, 2022
USD ($)
Dec. 31, 2023
EUR (€)
Aug. 21, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jul. 08, 2021
USD ($)
Aug. 31, 2019
USD ($)
Jul. 31, 2008
USD ($)
Feb. 28, 2005
USD ($)
Commitment And Contingencies [Line Items]                                          
Annual sales at the time of settlement $ 700,000,000                   $ 700,000,000               $ 350,000,000    
Annual sales of Effexor                           $ 2,600,000,000              
Annual sales of Lamictal                                       $ 2,300,000,000 $ 950,000,000
Annual sales of Niaspan           $ 1,100,000,000 $ 416,000,000                            
Annual sales of Actos               $ 2,800,000,000 $ 3,700,000,000                        
Annual sales of Acto plus               $ 430,000,000 $ 500,000,000                        
Litigation settlement amount         $ 4,250,000,000                                
Annual Sales Of Sensipar                       $ 1,400,000,000                  
Litigation settlement amount awarded distribution period         13 years                                
Annual sales of Copaxone                         $ 373,000,000                
Generic modafinil, and imposed fines amount 4,771,000,000                   4,771,000,000       € 60.5   $ 4,186,000,000        
Loss Contingency Accrual, Provision 235,500,000                                        
Annual sales of the time of settlement of viread                     582,000,000                    
Annual sales of the time of settlement of Truvada                     2,400,000,000                    
Annual sales of the time of settlement of Atripla                     2,900,000,000                    
Annual sales of the time of New launch of viread                     728,000,000                    
Annual sales of the time of New launch of Truvada                     2,100,000,000                    
Annual sales of the time of New launch of Atripla                     444,000,000                    
Annual sales of Colcrys                     187,000,000                    
Litigation Settlement Amount DistributableIn Kind 1,200,000,000                   1,200,000,000                    
Accrual for Environmental Loss Contingencies 300,000                   $ 300,000                    
Loss Contingencies On Environmental Laws Penalty                                   $ 1,400,000      
Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement                     99.00%                    
Annual Sales Of Revlimid 3,500,000,000                                        
Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer 300,000,000                                        
Annual Sales Of EpiPen 600,000,000                                        
Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population $ 1,000,000                                        
Percentage Of Share Of The National Population 1.00%                                        
Percentgae of amount in cash settlement 20.00%                   20.00%       20.00%            
Litigation Settlement Amount Distributable in cash $ 240,000,000                   $ 240,000,000                    
Loss Contingency, Damages Awarded, Value   $ 176,500,000                                      
NEVADA                                          
Commitment And Contingencies [Line Items]                                          
Loss Contingency, Settlement Agreement Terms         20 years                                
Payment         $ 193,000,000                                
Maximum [Member]                                          
Commitment And Contingencies [Line Items]                                          
Damage claimed                     1,000,000,000                    
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Donation of Clotrimazole and Tobramycin [Member]                                          
Commitment And Contingencies [Line Items]                                          
Other commitment                               $ 50,000,000          
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Fine for Violating the Antitrust Laws [Member]                                          
Commitment And Contingencies [Line Items]                                          
Other commitment, to be paid, year five                               135,000,000          
Other commitment to pay for each year                               22,500,000          
Other commitment                               $ 225,000,000          
Opioid Litigation [Member]                                          
Commitment And Contingencies [Line Items]                                          
Loss contingency accrual, product liability, undiscounted, to be paid, year five 368,000,000                   368,000,000                    
Loss contingency accrual, product liability, undiscounted, to be paid, year four 368,000,000                   368,000,000                    
Loss contingency accrual, product liability, undiscounted, to be paid, year three 364,000,000                   364,000,000                    
Loss contingency accrual, product liability, undiscounted, to be paid, year two 418,000,000                   418,000,000                    
Loss contingency accrual, product liability, undiscounted, to be paid, year one $ 424,000,000                   $ 424,000,000                    
Ontario Teachers Securities Litigation [Member] | Settled Litigation [Member]                                          
Commitment And Contingencies [Line Items]                                          
Litigation settlement amount     $ 420,000,000                                    
Litigation With US Hospitals And Other Healthcare Providers [Member]                                          
Commitment And Contingencies [Line Items]                                          
Litigation settlement amount       $ 126,000,000                                  
Litigation settlement amount awarded distribution period       18 years                                  
Product WAC Value       $ 49,000,000                                  
Product WAC Term       7 years                                  
Europe [Member]                                          
Commitment And Contingencies [Line Items]                                          
Damage claimed                   $ 50,000,000                      
Eosinophilic Esophagitis [Member]                                          
Commitment And Contingencies [Line Items]                                          
Damage claimed                   200,000,000                      
Eosinophilic Esophagitis [Member] | United States [Member]                                          
Commitment And Contingencies [Line Items]                                          
Damage claimed                   $ 150,000,000                      
AndroGel Rate at 1% [Member]                                          
Commitment And Contingencies [Line Items]                                          
Annual sales at the time of settlement                                     $ 140,000,000